Upregulation of PD-L1 by SARS-CoV-2 Promotes Immune Evasion
Overview
Authors
Affiliations
Patients with severe COVID-19 often suffer from lymphopenia, which is linked to T-cell sequestration, cytokine storm, and mortality. However, it remains largely unknown how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces lymphopenia. Here, we studied the transcriptomic profile and epigenomic alterations involved in cytokine production by SARS-CoV-2-infected cells. We adopted a reverse time-order gene coexpression network approach to analyze time-series RNA-sequencing data, revealing epigenetic modifications at the late stage of viral egress. Furthermore, we identified SARS-CoV-2-activated nuclear factor-κB (NF-κB) and interferon regulatory factor 1 (IRF1) pathways contributing to viral infection and COVID-19 severity through epigenetic analysis of H3K4me3 chromatin immunoprecipitation sequencing. Cross-referencing our transcriptomic and epigenomic data sets revealed that coupling NF-κB and IRF1 pathways mediate programmed death ligand-1 (PD-L1) immunosuppressive programs. Interestingly, we observed higher PD-L1 expression in Omicron-infected cells than SARS-CoV-2 infected cells. Blocking PD-L1 at an early stage of virally-infected AAV-hACE2 mice significantly recovered lymphocyte counts and lowered inflammatory cytokine levels. Our findings indicate that targeting the SARS-CoV-2-mediated NF-κB and IRF1-PD-L1 axis may represent an alternative strategy to reduce COVID-19 severity.
Subbarayan K, Bieber H, Massa C, Rodriguez F, Hossain S, Neuder L J Transl Med. 2025; 23(1):294.
PMID: 40055791 PMC: 11887338. DOI: 10.1186/s12967-025-06177-z.
Subbarayan K, Al-Samadi A, Schafer H, Massa C, Salo T, Biehl K Cell Mol Life Sci. 2024; 81(1):473.
PMID: 39625479 PMC: 11615173. DOI: 10.1007/s00018-024-05520-9.
Goens M, Howard E, Warner B, Susta L, Wootton S Viruses. 2024; 16(11).
PMID: 39599908 PMC: 11599079. DOI: 10.3390/v16111794.
The multiple roles of interferon regulatory factor family in health and disease.
Wang L, Zhu Y, Zhang N, Xian Y, Tang Y, Ye J Signal Transduct Target Ther. 2024; 9(1):282.
PMID: 39384770 PMC: 11486635. DOI: 10.1038/s41392-024-01980-4.
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders.
Lee D, Cho M, Kim E, Seo Y, Cha J Mol Ther. 2024; 32(12):4235-4255.
PMID: 39342430 PMC: 11638837. DOI: 10.1016/j.ymthe.2024.09.026.